Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 17/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2393326 | 0.95 | DGAT1 (0.44) | DGAT1ELANECNR2GLA | |
| SCHEMBL2397037 | 0.89 | DGAT1 (0.47) | DGAT1CNR2CYP3A4CYP2C9 | |
| SCHEMBL2390869 | 0.88 | DGAT1 (0.51) | DGAT1ELANECNR2CYP3A4CYP2C9 | |
| SCHEMBL2145526 | 0.88 | DGAT1 (0.51) | DGAT1ELANECNR2CYP3A4CYP2C9 | |
| SCHEMBL2145548 | 0.80 | DGAT1 (0.41) | DGAT1CNR2CYP3A4CYP2C9 | |
| SCHEMBL2146808 | 0.77 | DGAT1 (0.48) | DGAT1 | |
| SCHEMBL2145588 | 0.77 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL2145373 | 0.77 | DGAT1 (0.41) | DGAT1CYP3A4CYP2C9 | |
| SCHEMBL2145521 | 0.76 | DGAT1 (0.40) | DGAT1CNR2 | |
| SCHEMBL2396777 | 0.76 | DGAT1 (0.51) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716312-B2 | Inhibitors of diacylglycerol acyltransferase | MERCK SHARP & DOHME CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110224137-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP. | 2011-09-15 | — | — | US | disclosed |
| US-20110224137-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP. | 2011-09-15 | — | — | US | disclosed |
| US-20110224137-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP. | 2011-09-15 | — | — | US | disclosed |
| WO-2010059602-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224137-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DGAT1 2/4885ELANE 3549/4885CNR2 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.